GB2448627A - Combination therapy and antibody panels - Google Patents

Combination therapy and antibody panels

Info

Publication number
GB2448627A
GB2448627A GB0812408A GB0812408A GB2448627A GB 2448627 A GB2448627 A GB 2448627A GB 0812408 A GB0812408 A GB 0812408A GB 0812408 A GB0812408 A GB 0812408A GB 2448627 A GB2448627 A GB 2448627A
Authority
GB
United Kingdom
Prior art keywords
immunoglobulin
combination immunotherapy
combination therapy
idiotypic
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GB0812408A
Other versions
GB2448627B (en
GB0812408D0 (en
Inventor
Dan W Denney
Keri Marie Tate
Thomas P Theriault
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genitope Corp
Original Assignee
Genitope Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/297,167 external-priority patent/US20070134248A1/en
Priority claimed from US11/297,168 external-priority patent/US20070134249A1/en
Application filed by Genitope Corp filed Critical Genitope Corp
Publication of GB0812408D0 publication Critical patent/GB0812408D0/en
Publication of GB2448627A publication Critical patent/GB2448627A/en
Application granted granted Critical
Publication of GB2448627B publication Critical patent/GB2448627B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention is related to combination immunotherapy for malignancies such as Non-Hodgkin's Lymphoma (NHL) and chronic lymphocytic leukemia (CLL). In one embodiment, the combination immunotherapy first provides for the administration of a monoclonal antibody, or antibody fragment, directed to a non-idiotypic portion of an immunoglobulin or immunoglobulin-like molecule expressed on the surface of a malignant cell (e.g., a framework region of a variable region). The combination immunotherapy next provides for the administration of an immunogenic composition comprising at least a portion of the same malignant cell surface immunoglobulin, whether an idiotypic portion or non-idiotypic portion.
GB0812408A 2005-12-08 2008-07-07 Combination therapy and antibody panels Expired - Fee Related GB2448627B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/297,167 US20070134248A1 (en) 2005-12-08 2005-12-08 Combination therapy and antibody panels
US11/297,168 US20070134249A1 (en) 2005-12-08 2005-12-08 Combination therapy and antibody panels
PCT/US2006/047077 WO2007067780A2 (en) 2005-12-08 2006-12-08 Combination therapy and antibody panels

Publications (3)

Publication Number Publication Date
GB0812408D0 GB0812408D0 (en) 2008-08-13
GB2448627A true GB2448627A (en) 2008-10-22
GB2448627B GB2448627B (en) 2010-07-14

Family

ID=38123554

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0812408A Expired - Fee Related GB2448627B (en) 2005-12-08 2008-07-07 Combination therapy and antibody panels

Country Status (3)

Country Link
CA (1) CA2632744A1 (en)
GB (1) GB2448627B (en)
WO (1) WO2007067780A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2922212B1 (en) * 2007-10-11 2011-11-11 France Etat ANTIBODY ANTIBODY

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5227159A (en) * 1989-01-31 1993-07-13 Miller Richard A Anti-idiotype antibodies reactive with shared idiotopes expressed by B cell lymphomas and autoantibodies
US20030129628A1 (en) * 1992-03-09 2003-07-10 Sybille Muller Anti-idiotypic antibody and its use in diagnosis and therapy in HIV-related disease
US6706484B1 (en) * 1995-08-18 2004-03-16 Morphosys Ag Protein/(poly)peptide libraries

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5227159A (en) * 1989-01-31 1993-07-13 Miller Richard A Anti-idiotype antibodies reactive with shared idiotopes expressed by B cell lymphomas and autoantibodies
US20030129628A1 (en) * 1992-03-09 2003-07-10 Sybille Muller Anti-idiotypic antibody and its use in diagnosis and therapy in HIV-related disease
US6706484B1 (en) * 1995-08-18 2004-03-16 Morphosys Ag Protein/(poly)peptide libraries

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Blood, Vol.88, 1996, Nelson, et al., "Tunour-specific, cytotoxic T-lymphocytes...", pp.580-589 *
Blood, Vol.92, 1998, Davis, et al., "Anti-Idiotype antibodies can induce...", pp.1184-1190 *
Haematologica, Vol.87, 2002, Ruffini, et al ., "Idiotypic vaccination for B-cell...", pp.989-1001 *

Also Published As

Publication number Publication date
WO2007067780A2 (en) 2007-06-14
GB2448627B (en) 2010-07-14
GB0812408D0 (en) 2008-08-13
CA2632744A1 (en) 2007-06-14
WO2007067780A3 (en) 2008-05-02

Similar Documents

Publication Publication Date Title
WO2006029219A3 (en) Human monoclonal anti-ctla4 antibodies in cancer treatment
DE602005016773D1 (en) ANTIBODY ANTIBODIES WITH REDUCED COMPLEMENT FIXATION
ATE535547T1 (en) CROSS-LINKED ANTIBODIES
CL2010000788A1 (en) Monoclonal antibody or antigen binding fragment thereof that binds to integrin alpha-v-beta-6; pharmaceutical composition that includes it; use to treat or prevent fibrosis, psoriasis, cancer, acute lung damage and alpont syndrome; use to detect integrin alfa-v-beta-6 (div. sol. no. 513-03).
IL244803B (en) Humanized anti-beta7 antibodies and uses therefor
CY1111622T1 (en) ANTI-CMET HUMANIZED COMPETITORS
TW200833713A (en) Human antibodies that bind CD19 and uses thereof
WO2005103081A3 (en) Human monoclonal antibodies against cd20
WO2004005470A3 (en) Antibodies to non-shed muc1 and muc16, and uses thereof
PL2097453T3 (en) Monoclonal antibodies against the human anti-müllerian hormone type ii receptor (amhr-ii)
WO2003072036A3 (en) Treatment methods using anti-cd22 antibodies
TW200510459A (en) RG1 antibodies and uses thereof
UA114879C2 (en) CD38 ANTIBODY FOR CANCER TREATMENT
WO2005000901A3 (en) Cd20-specific antibodies and methods of employing same
ATE526987T1 (en) DR5 ANTIBODIES AND THEIR USE
WO2003048328A3 (en) Antibodies against carboxic anhydrase ix (ca ix) tumor antigen
ATE513857T1 (en) CELL SURFACE GLYCOPROTEINS FROM OVARY CANCER CELLS AND MYELOMA CELLS, THEIR ANTIBODIES AND USES THEREOF
HK1074670A1 (en) Sets of digital antibodies directed against short epitopes, and methods using same
SI1572087T1 (en) Antibodies against cancer antigen tmeff2 and uses thereof
ATE517920T1 (en) HUMANIZED ANTIBODIES AGAINST INTERFERON ALPHA RECEPTOR-1 (IFNAR-1)
WO2006029220A3 (en) Combination therapy with anti-ctla4 and anti-4-1bb antibodies
EA200970884A1 (en) METHODS OF TREATING CANCER BY INTRODUCING HUMAN INTERLEUKIN IL-18 COMBINATIONS
WO2008100563A3 (en) Compositions and methods for diagnosing and treating cancer
GB2448627A (en) Combination therapy and antibody panels
WO2007075706A3 (en) Affinity optimized epha2 agonistic antibodies and methods of use thereof

Legal Events

Date Code Title Description
PCNP Patent ceased through non-payment of renewal fee

Effective date: 20141208